GSA Capital Partners LLP Has $683,000 Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

GSA Capital Partners LLP lifted its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST) by 525.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 137,151 shares of the company’s stock after purchasing an additional 115,223 shares during the quarter. GSA Capital Partners LLP owned about 0.15% of Aquestive Therapeutics worth $683,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Aquestive Therapeutics by 71.7% during the first quarter. Vanguard Group Inc. now owns 3,242,571 shares of the company’s stock worth $13,813,000 after acquiring an additional 1,353,518 shares in the last quarter. Blue Owl Capital Holdings LP increased its holdings in Aquestive Therapeutics by 30.3% during the 2nd quarter. Blue Owl Capital Holdings LP now owns 1,140,000 shares of the company’s stock worth $2,964,000 after purchasing an additional 265,000 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in shares of Aquestive Therapeutics in the 2nd quarter valued at about $594,000. Chartwell Investment Partners LLC bought a new stake in shares of Aquestive Therapeutics in the third quarter valued at about $535,000. Finally, Lazard Asset Management LLC boosted its position in shares of Aquestive Therapeutics by 115.5% during the first quarter. Lazard Asset Management LLC now owns 29,112 shares of the company’s stock worth $124,000 after buying an additional 15,601 shares during the period. 32.45% of the stock is owned by institutional investors.

Aquestive Therapeutics Price Performance

Shares of AQST stock opened at $4.44 on Monday. The stock has a market cap of $404.84 million, a P/E ratio of -9.87 and a beta of 2.82. The company has a fifty day moving average price of $4.99 and a two-hundred day moving average price of $3.88. Aquestive Therapeutics, Inc. has a one year low of $1.61 and a one year high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The business had revenue of $13.54 million during the quarter, compared to analysts’ expectations of $12.69 million. During the same quarter in the previous year, the business posted ($0.03) earnings per share. As a group, equities research analysts anticipate that Aquestive Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AQST has been the topic of several research reports. Leerink Partners boosted their target price on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Aquestive Therapeutics in a research report on Wednesday, November 6th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $9.80.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.